Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

20141,068 citationsJournal Articlebronze Open Access

Authors

Robert J. Motzer · Roswell Park Comprehensive Cancer Center

Brian I. Rini · Roswell Park Comprehensive Cancer Center

David F. McDermott · Roswell Park Comprehensive Cancer Center

Bruce G. Redman · Roswell Park Comprehensive Cancer Center

Timothy M. Kuzel · Roswell Park Comprehensive Cancer Center

Michael R. Harrison · Roswell Park Comprehensive Cancer Center

Ulka N. Vaishampayan

Abstract

Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC. No dose-response relationship was detected as measured by PFS. These efficacy and safety results in mRCC support study in the phase III setting.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Renal cell carcinoma treatment CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 33, Issue 13, pp. 1430-1437

DOI: 10.1200/jco.2014.59.0703

Field-Weighted Citation Impact: 59.95